SGHT vs. TLSI, INO, ANGO, UTMD, NPCE, TMCI, GUTS, RCEL, TCMD, and PROF
Should you be buying Sight Sciences stock or one of its competitors? The main competitors of Sight Sciences include TriSalus Life Sciences (TLSI), Inovio Pharmaceuticals (INO), AngioDynamics (ANGO), Utah Medical Products (UTMD), NeuroPace (NPCE), Treace Medical Concepts (TMCI), Fractyl Health (GUTS), AVITA Medical (RCEL), Tactile Systems Technology (TCMD), and Profound Medical (PROF). These companies are all part of the "surgical & medical instruments" industry.
Sight Sciences (NASDAQ:SGHT) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.
55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 27.1% of Sight Sciences shares are owned by insiders. Comparatively, 76.2% of TriSalus Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Sight Sciences has higher revenue and earnings than TriSalus Life Sciences.
Sight Sciences received 14 more outperform votes than TriSalus Life Sciences when rated by MarketBeat users. However, 100.00% of users gave TriSalus Life Sciences an outperform vote while only 31.91% of users gave Sight Sciences an outperform vote.
In the previous week, TriSalus Life Sciences had 6 more articles in the media than Sight Sciences. MarketBeat recorded 7 mentions for TriSalus Life Sciences and 1 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.75 beat TriSalus Life Sciences' score of 0.23 indicating that Sight Sciences is being referred to more favorably in the media.
Sight Sciences has a beta of 2.73, suggesting that its share price is 173% more volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.
Sight Sciences currently has a consensus target price of $4.70, suggesting a potential downside of 11.99%. TriSalus Life Sciences has a consensus target price of $16.00, suggesting a potential upside of 62.44%. Given TriSalus Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe TriSalus Life Sciences is more favorable than Sight Sciences.
TriSalus Life Sciences has a net margin of 0.00% compared to Sight Sciences' net margin of -67.18%. TriSalus Life Sciences' return on equity of 0.00% beat Sight Sciences' return on equity.
Summary
TriSalus Life Sciences beats Sight Sciences on 8 of the 15 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sight Sciences Competitors List
Related Companies and Tools
